A Protein-Truncating HSD17B13 Variant and Protection from Chronic Liver Disease
Open accessThe DOI matches its Crossref record; 31 of the 32 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Elucidation of the genetic factors underlying chronic liver disease may reveal new therapeutic targets. METHODS: We used exome sequence data and electronic health records from 46,544 participants in the DiscovEHR human genetics study to identify genetic variants associated with serum levels of alanine aminotransferase (ALT) and aspartate aminotransferase (AST). Variants that were replicated in three additional cohorts (12,527 persons) were evaluated for association with clinical diagnoses of chronic liver disease in DiscovEHR study participants and two independent cohorts (total of 37,173 persons) and with histopathological severity of liver disease in 2391 human liver samples. RESULTS: ). Among DiscovEHR study participants, this variant was associated with a reduced risk of alcoholic liver disease (by 42% [95% confidence interval {CI}, 20 to 58] among heterozygotes and by 53% [95% CI, 3 to 77] among homozygotes), nonalcoholic liver disease (by 17% [95% CI, 8 to 25] among heterozygotes and by 30% [95% CI, 13 to 43] among homozygotes), alcoholic cirrhosis (by 42% [95% CI, 14 to 61] among heterozygotes and by 73% [95% CI, 15 to 91] among homozygotes), and nonalcoholic cirrhosis (by 26% [95% CI, 7 to 40] among heterozygotes and by 49% [95% CI, 15 to 69] among homozygotes). Associations were confirmed in two independent cohorts. The rs72613567:TA variant was associated with a reduced risk of nonalcoholic steatohepatitis, but not steatosis, in human liver samples. The rs72613567:TA variant mitigated liver injury associated with the risk-increasing PNPLA3 p.I148M allele and resulted in an unstable and truncated protein with reduced enzymatic activity. CONCLUSIONS: A loss-of-function variant in HSD17B13 was associated with a reduced risk of chronic liver disease and of progression from steatosis to steatohepatitis. (Funded by Regeneron Pharmaceuticals and others.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Besides PNPLA3 p.I148M and TM6SF2 p.E167K, additional variants, including common risk variants in MBOAT7 , GCKR , GPAM , protective variants in HSD17B13 , APOE and MTARC1, and rare variants ( e.g. in APOB , MTTP, CIDEB and ATG7 ), have been robustly associated with the risk of progressive MASLD. 199 -205”
From EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). (2024) · cites this paper as [200]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Mutations in the periportal hepatocyte-enriched genes HSD17B13152 and PNPLA3153 are associated with NASH”
From Distinct hepatocyte identities in liver homeostasis and regeneration (2023) · cites this paper as [152]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Some of the most important human metabolic disease genes have been identified using germline genetic methods such as GWAS and whole exome sequencing42-44.”
From Positive selection of somatically mutated clones identifies adaptive pathways in metabolic liver disease (2023) · cites this paper as [43]
The cited source says what the claim attributes to it.
In the citing paper
“To demonstrate this, we examined the trans associations with a splice variant in HSD17B13 (rs72613567), known to protect against chronic liver disease42.”
From Rare variant associations with plasma protein levels in the UK Biobank (2023) · cites this paper as [42]
In the citing paper
“These findings inform the prioritization of therapeutic targets, providing clues to potential on-target side effects and opportunities for drug repurposing87–89.”
From A brief history of human disease genetics (2020) · cites this paper as [88]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Prevalence of Hepatic Steatosis in An Urban Population in the United States: Impact of Ethnicity
Browning, J. D., Szczepaniak, L. S., Dobbins, R., Nuremberg, P., Horton, J. D., Cohen, J. C., Grundy, S. M., & Hobbs, H. H. (2004) · Hepatology · doi:10.1002/hep.20466 · Cited by 3,664
Self-citationGenetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease
Romeo, S., Kozlitina, J., Xing, C., Pertsemlidis, A., Cox, D., Pennacchio, L. A., Boerwinkle, E., Cohen, J. C., & Hobbs, H. H. (2008) · Nature Genetics · doi:10.1038/ng.257 · Cited by 3,416
Self-citationWilliams, C. D., Stengel, J., Asike, M. I., Torres, D. M., Shaw, J., Contreras, M., Landt, C. L., & Harrison, S. A. (2011) · Gastroenterology · doi:10.1053/j.gastro.2010.09.038 · Cited by 2,148
Human Fatty Liver Disease: Old Questions and New Insights
Cohen, J. C., Horton, J. D., & Hobbs, H. H. (2011) · Science · doi:10.1126/science.1204265 · Cited by 2,089
Self-citationKozlitina, J., Smagris, E., Stender, S., Nordestgaard, B. G., Zhou, H. H., Tybjærg-Hansen, A., Vogt, T. F., Hobbs, H. H., & Cohen, J. C. (2014) · Nature Genetics · doi:10.1038/ng.2901 · Cited by 1,234
Self-citationYounossi, Z. M., Stepanova, M., Afendy, M., Fang, Y., Younossi, Y., Mir, H., & Srishord, M. (2011) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2011.03.020 · Cited by 1,073
Lazo, M., Hernaez, R., Eberhardt, M. S., Bonekamp, S., Kamel, I., Guallar, E., Koteish, A., Brancati, F. L., & Clark, J. M. (2013) · American Journal of Epidemiology · doi:10.1093/aje/kws448 · Cited by 797
Mancina, R. M., Dongiovanni, P., Petta, S., Pingitore, P., Meroni, M., Rametta, R., Borén, J., Montalcini, T., Pujia, A., Wiklund, O., et al. (2016) · Gastroenterology · doi:10.1053/j.gastro.2016.01.032 · Cited by 676
Self-citationLiu, Y.-L., Reeves, H. L., Burt, A. D., Tiniakos, D., McPherson, S., Leathart, J. B. S., Allison, M. E. D., Alexander, G. J., Piguet, A.-C., Anty, R., et al. (2014) · Nature Communications · doi:10.1038/ncomms5309 · Cited by 623
Self-citationBuch, S., Stickel, F., Trépo, E., Way, M., Herrmann, A., Nischalke, H. D., Brosch, M., Rosendahl, J., Berg, T., Ridinger, M., et al. (2015) · Nature Genetics · doi:10.1038/ng.3417 · Cited by 565
Cited by
Items 501–600 of 831
Seko, Y., Yamaguchi, K., Yano, K., Takahashi, Y., Takeuchi, K., Kataoka, S., Moriguchi, M., & Itoh, Y. (2022) · Scientific Reports · doi:10.1038/s41598-022-22729-5 · Cited by 11
Thomes, P. G., Strupp, M. S., Donohue, T. M., Kubik, J. L., Sweeney, S. A., Mahmud, R., Schott, M. B., Schulze, R. J., McNiven, M. A., & Casey, C. A. (2023) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2023.103071 · Cited by 10
Phenyl dialkynylcarbinols, a Bioinspired Series of Synthetic Antitumor Acetylenic Lipids
Bossuat, M., Rullière, P., Preuilh, N., Peixoto, A., Joly, E., Gomez, J.-G., Bourkhis, M., Rodriguez, F., Gonçalves, F. A., Fabing, I., et al. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c00859 · Cited by 10
Interleukin-2 receptor alpha as a biomarker for nonalcoholic fatty liver disease diagnosis
Kao, W., Lin, Y., Chang, I., Chen, C., Tang, J., Chang, C., Chang, Y., & Wang, W. (2020) · Journal of the Chinese Medical Association · doi:10.1097/jcma.0000000000000469 · Cited by 13
Balcar, L., Semmler, G., Oberkofler, H., Zandanell, S., Straßer, M., Datz, L., Niederseer, D., Feldman, A., Stickel, F., Datz, C., et al. (2021) · Digestive and Liver Disease · doi:10.1016/j.dld.2021.06.015 · Cited by 13
An HSD17B13 variant reduces cirrhosis risk
Thomas, H. (2018) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-018-0016-7 · Cited by 10
Garber, K. (2019) · Nature Biotechnology · doi:10.1038/s41587-019-0047-9 · Cited by 10
Genome-wide association study of liver fat, iron, and extracellular fluid fraction in the UK BiobankPreprint
O’Dushlaine, C. T., Germino, M., Verweij, N., Nielsen, J. B., Yadav, A. K., Benner, C., Backman, J., Lin, N., Abecasis, G. R., Baras, A., et al. (2021) · medRxiv · doi:10.1101/2021.10.25.21265127 · Cited by 11
Self-citationRieman‐Klingler, M. C., Jung, J., Tesfai, K., Loomba, R. S., & Non, A. L. (2024) · American Journal of Biological Anthropology · doi:10.1002/ajpa.24979 · Cited by 10
“In contrast, an additional variant of particular interest is a protective protein-truncating splice variant (rs72613567:TA) in HSD17B13 (Abul-Husn et al., 2018; Amangurbanova et al., 2023), a gene encoding a hepatic lipid droplet protein, 17 β -hydroxysteroid dehydrogenase-13, involved in…”
InfluentialRecent advances in the development of 17beta-hydroxysteroid dehydrogenase inhibitors
Poirier, D. (2024) · Steroids · doi:10.1016/j.steroids.2024.109529 · Cited by 14
“This oxidative member of the 17β-HSD family was recently identified as a potential new target for the treatment of non-alcoholic steatohepatitis (NASH) and other liver diseases from genome-wide association studies [141].”
Koeberle, S. C., Thürmer, M., Werner, M., Grander, J., Hofer, L., Gollowitzer, A., Su, F., Xuan, L. L., Benscheid, F. J., Rad, E. B., et al. (2025) · Theranostics · doi:10.7150/thno.99562 · Cited by 13
“…biosynthesis and remodeling (LPIAT1/MBOAT7, iPLA2/PLA2G6, PNPLA8, PRDX6, PLD1)[23-29], neutral and phospholipid hydrolysis and catabolism (PNPLA3)[30], sterol metabolism ( HSD17B13)[31] fatty acid compartmentalization (GCKR, TM6SF2), and lipoprotein assembly and secretion (PLA2G7, TM6SF2)[26].”
James, G., Reisberg, S., Lepik, K., Galwey, N. W., Avillach, P., Kolberg, L., Mägi, R., Esko, T., Alexander, M., Waterworth, D. M., et al. (2019) · PLoS ONE · doi:10.1371/journal.pone.0215026 · Cited by 10
Liver specific, systemic and genetic contributors to alcohol-related liver disease progression
Schnabl, B., Arteel, G. E., Stickel, F., Hengstler, J. G., Vartak, N., Ghallab, A., Dooley, S., Li, Y., & Schwabe, R. F. (2022) · Zeitschrift für Gastroenterologie · doi:10.1055/a-1714-9330 · Cited by 10
“…2 ( TM6SF2 ) [68], membrane bound O-acyltransferase domain containing 7 ( MBOAT7 ) [68], hy-droxysteroid 17-beta dehydrogenase 13 ( HSD17B13 ) [69, 70], mitochondrial amidoxime reducing component 1 ( MARC1 ) [71], heterogeneous nuclear ribonucleoprotein U like 1 ( HNRNPUL1 ) [71], and…”
Silva, L. F., Vangipurapu, J., Oravilahti, A., Männistö, V., & Laakso, M. (2023) · Metabolites · doi:10.3390/metabo13020267 · Cited by 9
“The HSD17B13 rs72613567:TA variant has an insertion of the A allele (TA/TA-homozygous) and encodes for the hepatic lipid droplet protein hydroxysteroid 17-beta dehydrogenase 13 and reduces the risk of liver fibrosis and steatosis [14,16].”
BackgroundResultFassio, E., Barreyro, F. J., Pérez, M. S., Dávila, D., Landeira, G., Gualano, G., & Ruffillo, G. (2022) · World Journal of Hepatology · doi:10.4254/wjh.v14.i2.354 · Cited by 14
Generation of a Diet-Induced Mouse Model of Nonalcoholic Fatty Liver Disease
Asgharpour, A., & Sanyal, A. J. (2022) · Methods in molecular biology · doi:10.1007/978-1-0716-2128-8_2 · Cited by 8
Seidelin, A.-S., Nordestgaard, B. G., Tybjærg‐Hansen, A., Yaghootkar, H., & Stender, S. (2022) · Hepatology International · doi:10.1007/s12072-022-10331-w · Cited by 8
Self-citationEmerging Biomarkers in Alcohol-associated Hepatitis
Im, G. Y. (2022) · Journal of Clinical and Experimental Hepatology · doi:10.1016/j.jceh.2022.07.246 · Cited by 11
Smyk, W., Papapostoli, I., Żorniak, M., Sklavounos, P., Blukacz, Ł., Madej, P., Koutsou, A., Weber, S. N., Friesenhahn‐Ochs, B., Cebula, M., et al. (2023) · Liver International · doi:10.1111/liv.15527 · Cited by 10
Analysis of genetic factors associated with fatty liver disease‐related hepatocellular carcinoma
Kogiso, T., Ogasawara, Y., Horiuchi, K., Taniai, M., & Tokushige, K. (2023) · Cancer Medicine · doi:10.1002/cam4.6410 · Cited by 9
Güldiken, N., Hamesch, K., Schuller, S., Aly, M., Lindhauer, C., Schneider, C. V., Fromme, M., Trautwein, C., & Strnad, P. (2019) · Cells · doi:10.3390/cells8111415 · Cited by 9
Genomic Signatures of MASLD: How Genomics Is Redefining Our Understanding of Metabolic Liver Disease
Saliba‐Gustafsson, P., Härdfeldt, J., Pedrelli, M., & Parini, P. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms262210881 · Cited by 10
Beyond fat accumulation, NAFLD genetics converges on lipid droplet biology
Baselli, G., & Valenti, L. V. C. (2018) · Journal of Lipid Research · doi:10.1194/jlr.c091116 · Cited by 9
“Therefore, despite limitations of the relatively small sample size, this study provides a nice validation of previous findings observed in Caucasians in a cohort of individuals of different ethnicity, which was characterized by a lower prevalence of the variant under study (6, 7).”
BackgroundResultInfluentialLazar, M. V., Eapen, M., Nair, H. R., Siyad, I., & Rajesh, G. (2020) · Indian Journal of Gastroenterology · doi:10.1007/s12664-020-01024-z · Cited by 8
“Interestingly, in a recent study [26], loss-of-function variant in HSD17B13 was found to be associated with a reduced risk of chronic liver disease.”
BackgroundSaiman, Y., Hooks, R., & Carr, R. M. (2020) · Current Hepatology Reports · doi:10.1007/s11901-020-00539-5 · Cited by 9
Metabolic and genetic contributions to NAFLD: Really distinct and homogeneous?
Speliotes, E. K., & George, J. (2021) · Journal of Hepatology · doi:10.1016/j.jhep.2021.12.024 · Cited by 8
The association of non‐alcoholic fatty liver disease between parents and adolescent children
Park, Y., Sinn, D. H., Kim, K., & Gwak, G. (2022) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.17257 · Cited by 8
Prognostication in NAFLD: physiological bases, clinical indicators, and newer biomarkers
Terracciani, F., Falcomatà, A., Gallo, P., Picardi, A., & Gentilucci, U. V. (2022) · Journal of Physiology and Biochemistry · doi:10.1007/s13105-022-00934-0 · Cited by 9
“However, the precise mechanisms by which the variant contributes to these effects are far from being elucidated; notably, the SNP has not been consistently associated with a reduction of hepatic triglyceride content [48].”
BackgroundGenetic Aspects of Non-Alcoholic Fatty Liver Disease
Bogomolov, P., Kokina, K. Y., Mayorov, A. Y., & Mishina, E. Е. (2019) · Вопросы современной педиатрии · doi:10.15690/vsp.v17i6.1974 · Cited by 14
“Ген HSD17B13 экспрессируется преимущественно в гепатоцитах, а белковый продукт гена локализуется в липидных каплях [46].”
Sekundäre Ursachen der Fettleber – Neues zur Pathogenese, rationalen Diagnostik und Therapie
Keitel, V., Dahl, S. V., & Häussinger, D. (2020) · DMW - Deutsche Medizinische Wochenschrift · doi:10.1055/a-0965-9648 · Cited by 9
“Kürzlich wurde darüber hinaus eine Insertionsvariante im Gen der 17-beta-Hydroxysteroid-Dehydrogenase (rs726 113 567) identifiziert, die das Risiko für ein Fortschreiten einer bereits vorhandenen Steatose zu NASH und zu NASH-Fibrose signifikant reduziert [15].”
BackgroundUncovering the genetics of cirrhosis: New plots for the usual suspects
Valenti, L. V. C. (2020) · Liver International · doi:10.1111/liv.14333 · Cited by 8
TINIAKOS, D. G., Anstee, Q. M., Brunt, E. M., & Burt, A. D. (2023) · Elsevier eBooks · doi:10.1016/b978-0-7020-8228-3.00005-3 · Cited by 9
GCKIII kinases control hepatocellular lipid homeostasis via shared mode of action
Cansby, E., Caputo, M., Andersson, E., Saghaleyni, R., Henricsson, M., Xia, Y., Asiedu, B., Blüher, M., Svensson, L. T., Hoy, A. J., et al. (2024) · Journal of Lipid Research · doi:10.1016/j.jlr.2024.100669 · Cited by 8
“This knowledge can lay a platform for future investigations aimed at identifying novel targets for the prevention and/or treatment of MASLD and MASH, which remain major clinical challenges.”
InfluentialGene-based therapies for steatotic liver disease
Iakovleva, V., & de Jong, Y. P. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.04.024 · Cited by 9
“87 While both mouse and human hepatocytes express HSD17B13, germline Hsd17b13 (cid:0) / (cid:0) mice developed hepatic steatosis on a high-fat diet (HFD) as wild-type (WT) mice, or when fed a liquid diet containing alcohol.”
Ojeda, D. F. G., Yalcin, Y., Pita-Juárez, Y. H., Hakim, A., Bhattarai, S., Chen, Z., Asara, J. M., Connelly, M. A., Miller, M. R., Lai, M., et al. (2025) · Hepatology Communications · doi:10.1097/hc9.0000000000000716 · Cited by 16
MetALD: Genetic Factors and Clinical Outcomes
Israelsen, M. E., Trépo, E., Krag, A. A., & Stender, S. (2025) · Seminars in Liver Disease · doi:10.1055/a-2630-0952 · Cited by 9
“35 In this review, we have chosen to focus on variants and genes that have been robustly and reproducibly associated with hepatic steatosis and the related outcomes in large-scale genome-wide association studies (GWAS).”
Self-citationKaushal, K., Singh, S., Anand, A., Ramakrishna, G., Kale, P. R., Sharma, R., Rewari, B. B., & Sarin, S. K. (2026) · Journal of Clinical and Experimental Hepatology · doi:10.1016/j.jceh.2026.103533 · Cited by 11
Gómez, E. V., Liang, T., Yates, K. P., Wilson, L., Loomba, R. S., & Chalasani, N. (2022) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2022.11.002 · Cited by 9
Lipid droplets as the genetic nexus of fatty liver
Mann, J. P., Romeo, S., & Valenti, L. V. C. (2022) · Liver International · doi:10.1111/liv.15460 · Cited by 7
Ji, S., Qu, Y., Sun, Q., Zhao, F., Qiu, Y., Li, Z., Li, Y., Song, H., Zhang, M., Zhang, W., et al. (2024) · Environmental Science & Technology · doi:10.1021/acs.est.3c08718 · Cited by 7
Garnsey, M. R., Wang, Y., Edmonds, D. J., Sammons, M. F., Reidich, B., Ahn, Y., Ashkenazi, Y., Carlo, A. A., Cerny, M. A., Coffman, K. J., et al. (2025) · Nature Communications · doi:10.1038/s41467-024-54487-5 · Cited by 7
“…of HSD17B13; and utilizing these substrates compare enzymatic activity between common HSD17B13 variants, demonstrating that the A allele insertion variant (IsoD), previously thought to be a loss-of-function variant, retains enzymatic activity for LTB4 and a synthetic substrate, while other…”
Impact of Weight Loss on Metabolic Dysfunction Associated Steatohepatitis and Hepatic Fibrosis
Takawy, M., & Abdelmalek, M. F. (2025) · Current Diabetes Reports · doi:10.1007/s11892-025-01579-1 · Cited by 14
“…hepatocyte uric acid production, energy surplus, imbalance between fatty acid uptake and fatty acid disposal, and intrahepatic lipids], contribute to heterogeneity in disease activity and fibrosis progression or regression [48, 56–63] and are beyond the scope of further discussion in this review.”
Phen, C., & Ramirez, C. M. (2021) · Clinical Liver Disease · doi:10.1002/cld.1008 · Cited by 7
HCC in metabolic syndrome: current concepts and future directions
Zampaglione, L., Ferrari, J., Pedica, F., & Goossens, N. (2021) · Hepatoma Research · doi:10.20517/2394-5079.2021.22 · Cited by 9
Molecular mechanisms of liver carcinogenesis related to metabolic syndrome
Campani, C., & Nault, J. (2022) · Hepatoma Research · doi:10.20517/2394-5079.2021.126 · Cited by 9
Yang, Z., Han, S., Zhang, T., Kusumanchi, P., Huda, N., Tyler, K., Chandler, K., Skill, N. J., Tu, W., Shan, M., et al. (2022) · Hepatology Communications · doi:10.1002/hep4.1903 · Cited by 7
Mann, J. P., & Hoare, M. (2022) · Liver International · doi:10.1111/liv.15283 · Cited by 8
Zhao, W., Mori, H., Tomiga, Y., Tanaka, K., Perveen, R., Mine, K., Inadomi, C., Yoshioka, W., Kubotsu, Y., Isoda, H., et al. (2022) · Genes · doi:10.3390/genes13071265 · Cited by 7
Nischalke, H. D., Schmalz, F., Buch, S., Fischer, J., Möller, C., Matz‐Soja, M., Krämer, B., Langhans, B., Klüners, A., Soyka, M., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232315353 · Cited by 7
“Different genetic loci were discovered and validated in large patient cohorts, with some increasing the risk for HCC, such as the presence of the PNPLA3 minor variant 148M [1,7,8], and with others reducing the risk, such as the HSD17B13 rs72613567:TA variant [9,10].”
BackgroundMungamuri, S. K., Gupta, Y. K., Rao, P. N., & Ravishankar, B. (2023) · Gene Expression · doi:10.14218/ge.2022.00014 · Cited by 11
The role of lipid droplet associated proteins in inherited human disorders
Duan, X., & Savage, D. B. (2023) · FEBS Letters · doi:10.1002/1873-3468.14779 · Cited by 8
Genetics and epidemiology of AATD
Hobbs, B. D., Silverman, E. K., & Cho, M. H. (2019) · European Respiratory Society eBooks · doi:10.1183/2312508x.10013119 · Cited by 7
Alpha-1 antitrypsin deficiency
Fromme, M., & Strnad, P. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-98368-6.00005-7 · Cited by 7
Hudert, C. A., Alisi, A., Anstee, Q. M., Crudele, A., Draijer, L. G., EU-PNAFLD investigators, Furse, S., Hengstler, J. G., Jenkins, B., Karnebeek, K., et al. (2020) · medRxiv · doi:10.1101/2020.06.05.20120956 · Cited by 7
Human genetic evidence supports MAP3K15 inhibition as a therapeutic strategy for diabetesPreprint
Nag, A., Dhindsa, R. S., Harper, A. R., Vitsios, D., Ahnmark, A., Bilican, B., Madeyski-Bengtson, K., Zarrouki, B., Wang, Q., Smith, K. R., et al. (2021) · medRxiv · doi:10.1101/2021.11.14.21266328 · Cited by 7
Jiang, J., Liu, Y., Yang, H., Ma, Z., Liu, W., Zhao, M., Peng, X., Qin, X., & Yang, X. (2025) · Food Research International · doi:10.1016/j.foodres.2025.116497 · Cited by 8
Self-citationAlternative Splicing Regulation in Metabolic Disorders
Kamińska, D. (2025) · Obesity Reviews · doi:10.1111/obr.13950 · Cited by 8
Sharma, T., Kaushal, N., & Garla, R. (2025) · World Journal of Hepatology · doi:10.4254/wjh.v17.i8.108772 · Cited by 6
Dj, H., Zhang, Z., Dorajoo, R., Khor, C. C., Pham, Y. T., Wang, R., Behari, J., Yuan, J., Koh, W., & Luu, H. N. (2026) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.70532 · Cited by 9
“…with HCC risk, but translating their use to routine clinical practice is challenging, partly related to the influence of epigenetics and environmental factors, varying risk allele frequencies across population groups, and a lack of knowledge and guidance among disease specialists [17, 36, 37].”
Trépo, E., Zucman‐Rossi, J., & Nault, J. (2026) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-026-01175-y · Cited by 6
“The shared genetic architecture between MASLD and ALD suggests common therapeutic targets, whereas emerging MetALD represents a distinct entity requiring dedicated genetic investigation.”
InfluentialMASLD, diabetes and PMOS across the female life stages
Stener‐Victorin, E., Carlsson, S., Hagström, H., & Taebnia, N. (2026) · Diabetologia · doi:10.1007/s00125-026-06761-y · Cited by 7
“Conversely, protective variants in HSD17B13 (rs72613567) and MTARC1 (rs2642438, A165T) reduce the risk of progression to advanced liver disease [44, 45].”
Exome sequencing identifies novel genetic variants associated with varicose veins
Zhang, D.-D., He, X., Liu, Y., Wu, B., Fu, Y. H. H., Liu, W., Guo, Y., Fei, C.-J., Kang, J., Feng, J.-F., et al. (2024) · PLoS Genetics · doi:10.1371/journal.pgen.1011339 · Cited by 6
Self-citationAlcohol consumption and liver phenotype of individuals with alpha‐1 antitrypsin deficiency
Fromme, M., Schneider, C. V., Güldiken, N., Amzou, S., Luo, Y., Pons, M., Genescà, J., Miravitlles, M., Thorhauge, K. H., Mandorfer, M., et al. (2024) · Liver International · doi:10.1111/liv.16044 · Cited by 6
“4,9,10 In contrast, the impact of moderate alcohol consumption as well as the impact of alcohol in Pi*ZZ individuals remains to be systematically examined.”
Management of non-alcoholic fatty liver disease-associated hepatocellular carcinoma
Xu, P., Liu, M., Liu, M., & Shen, A. (2024) · BioScience Trends · doi:10.5582/bst.2024.01295 · Cited by 7
Chen, V. L., & Brady, G. F. (2025) · Hepatology Communications · doi:10.1097/hc9.0000000000000618 · Cited by 11
Nonalcoholic Fatty Liver Disease
Bergasa, N. V. (2021) · Springer eBooks · doi:10.1007/978-1-4471-4715-2_9 · Cited by 6
Lanzaro, F., Guarino, S., D’Addio, E., Salvatori, A., D’Anna, J. A., Marzuillo, P., del Giudice, E. M., & Sessa, A. D. (2022) · World Journal of Hepatology · doi:10.4254/wjh.v14.i6.1087 · Cited by 5
Semmler, G., Balcar, L., Wernly, S., Datz, L., Semmler, M., Rosenstatter, L., Stickel, F., Aigner, E. S., Wernly, B., & Datz, C. (2023) · Wiener klinische Wochenschrift · doi:10.1007/s00508-023-02196-2 · Cited by 7
“Following the identification of PNPLA3 , other single nucleotide polymorphisms (SNP) such as the Transmembrane 6 Super-family 2 (TM6SF2) rs58542926, SERPINA1, MBOAT7 , or HSD17B13 were found to modify disease progression of NAFLD in genome-wide association studies (GWAS) [5–8].”
InfluentialWu, H.-C., Hsieh, Y.-R., Wang, W., Chang, C.-W., Chang, I., Chen, C., Chang, C., Chang, C., Kao, W., & Huang, S. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12113730 · Cited by 8
Thüne, K., Schmitz, M., Villar‐Piqué, A., Altmeppen, H. C., Schlomm, M., Zafar, S., Glatzel, M., Llorens, F., & Zerr, I. (2019) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2019.1667231 · Cited by 6
“protective mechanisms against different diseases [18,19].”
Hepatocellular Carcinoma Risk Stratification by Genetic Profiling in Patients with Cirrhosis
Fujiwara, N., & Hoshida, Y. (2019) · Seminars in Liver Disease · doi:10.1055/s-0039-1681031 · Cited by 6
Non-alcoholic Fatty Liver Disease: A Global Public Health Issue
Kaya, E., & Yilmaz, Y. N. (2020) · Springer eBooks · doi:10.1007/978-3-030-53370-0_24 · Cited by 10
Zoller, H., Wagner, S., & Tilg, H. (2020) · Gastroenterology · doi:10.1053/j.gastro.2020.06.035 · Cited by 6
Lyon, M., Millard, L. A. C., Smith, G. D., Gaunt, T. R., & Tilling, K. M. (2022) · medRxiv · doi:10.1101/2022.01.05.21268406 · Cited by 6
Herms, Q., Gratacós‐Ginès, J., & Pose, E. (2025) · Gastroenterology report · doi:10.1093/gastro/goaf088 · Cited by 5
Fu, B., Pazokitoroudi, A., Shi, Z., Kar, A., Xue, A., Anand, A., Anand, P., Liu, Z., Border, R., Pajukanta, P., et al. (2025) · Nature Genetics · doi:10.1038/s41588-025-02411-y · Cited by 17
Exome sequencing and analysis of 44,028 British South Asians enriched for high autozygosity
Kim, H. I., DeBoever, C., Walter, K., Kalantzis, G., Li, C., Mozaffari, S. V., Kundu, K., Jacobs, B. M., Mohammadi‐Shemirani, P., Musolf, A. M., et al. (2026) · Nature Genetics · doi:10.1038/s41588-026-02553-7 · Cited by 12
“One example is HSD17B13, which is targeted by several RNA interference therapeutics for the treatment of non-alcoholic liver diseases based on a gene–phenotype association identified through genetic studies 58 .”
Genetics of MASLD: a diabetes perspective
Bilson, J., & Yaghootkar, H. (2026) · Diabetologia · doi:10.1007/s00125-026-06759-6 · Cited by 9
“Loss-of-function variants protect against steatohepatitis and advanced liver disease [16].”
Crane, J. D., Barrandon, O., Faherty, B., Gorgoglione, M., Crowley, C., Morin, J., Ross, T. T., Shimkonis, J., Li, D., Hirenallur-Shanthappa, D. K., et al. (2024) · Journal of Lipid Research · doi:10.1016/j.jlr.2024.100634 · Cited by 5
Younossi, Z. M., Estep, J. M., Felix, S. C., Lam, B. P., Younossi, Z., Racila, A., & Stepanova, M. (2024) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2024.111960 · Cited by 5
Paredes-Marin, A., Napoli, J., Sivakumar, V., Near, C., Adams, H., Harty, A., Agarwal, R., Dieterich, D. T., Bucuvalas, J. C., Kushner, T., et al. (2025) · Digestive Diseases and Sciences · doi:10.1007/s10620-025-09138-0 · Cited by 5
“…with whole exome sequencing, in conjunction with registered patients, analyzing samples for the PNPLA3 rs738409 C/G polymorphism and the HSD17B13 rs72613567 loss of function could be accomplished and would offer additional information on the interplay of genetics and the environment [8, 29].”
Burlone, M. E., Bellan, M., Barbaglia, M. N., Mocchetti, G., Mallela, V. R., Minisini, R., Rigamonti, C., & Pirisi, M. (2022) · Clinical Journal of Gastroenterology · doi:10.1007/s12328-021-01578-1 · Cited by 6
“Carriage of the protein-truncating variant of HSD17B13 is associated with lower levels of transaminases and with a lower risk of alcoholic liver disease and NAFLD in adults, as well as with lower hepatic steatosis in obese children [18, 41].”
BackgroundMethodMücke, V. T., Fischer, J., Mücke, M. M., Teumer, A., Koch, A. H., Vermehren, J., Fromme, M., Zeuzem, S., Trautwein, C., Sarrazin, C., et al. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm12010253 · Cited by 5
Lv, Y., Ding, D., Luo, M., Tan, X. W., Yang, X., & Chen, L. (2023) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2023.01.011 · Cited by 5
NASH/NAFLD-Related Hepatocellular Carcinoma: An Added Burden
Georgescu, D., Lighezan, D., Rosca, C. I., Nistor, D., Ancusa, O., Suceava, I., Iancu, M. A., & Kundnani, N. R. (2023) · Life · doi:10.3390/life14010025 · Cited by 6
“A mutation in 17ß-hydroxysteroid dehydrogenase type 13 was also identified, with a protective effect in the occurrence of HCC in patients with NAFLD, also preventing the onset of severe liver fibrosis [43].”
BackgroundFu, S., Carlson, L., Peterson, K. J., Wang, N., Zhou, X., Peng, S., Jiang, J., Wang, Y., Sauver, J. L. S., & Liu, H. (2020) · PubMed Central · Cited by 8
Current and Future Biomarkers in Alcoholic Hepatitis
Rutledge, S. M., & Im, G. Y. (2021) · Clinics in Liver Disease · doi:10.1016/j.cld.2021.03.010 · Cited by 6
Innes, H. A., Walker, A. J., Benselin, J., Grove, J. I., Pedergnana, V., Ansari, M. A., Lin, S., McLauchlan, J., Hutchinson, S. J., Barnes, E. J., et al. (2022) · Clinical and Translational Gastroenterology · doi:10.14309/ctg.0000000000000462 · Cited by 6
Norden‐Krichmar, T. M., Rotroff, D. M., Schwantes-An, T.-H. L., Bataller, R. A., Goldman, D. A., Nagy, L. E., & Liangpunsakul, S. (2023) · Hepatology · doi:10.1097/hep.0000000000000617 · Cited by 8
Meroni, M., Longo, M., & Dongiovanni, P. (2020) · Exploration of Medicine · doi:10.37349/emed.2020.00015 · Cited by 5
“According to these results, the E167K TM6SF2 did not influence fibrosis severity in 694 consecutively biopsied Caucasians with chronic hepatitis C [95] whereas it correlated with alcohol-related HCC in 511 cirrhotic patients [96] and in a prospective cohort of 249 ALD patients [97].”
BackgroundInfluentialGokuladhas, S., Schierding, W. S., Fadason, T., Choi, M., & O'Sullivan, J. M. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.12.08.471841 · Cited by 5
“Moreover, although genes (e.g. PNPLA3, TM6SF2, GCKR, HSD17B13) have been mapped to NAFLD-associated variants by GWAS, these mappings are not supported in the LGRN.”
InfluentialBale, G., Anand, V. K., Rao, P. N., Menon, P. B., Mithun, S., Sasikala, M., Sowmya, T. R., Sekaran, A., Smita, C. P., Reddy, D. N., et al. (2024) · Journal of Clinical and Experimental Hepatology · doi:10.1016/j.jceh.2024.101371 · Cited by 4
Targeting CIDEB alleviates liver steatosis and fibrosis in mouse MASH models
Lin, Y., Fan, F., Mo, Z., Huang, Z., Zhou, M., Ma, Y., Qian, C., Wang, Y., Qian, C., & Liu, X. (2025) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2025.102567 · Cited by 4
Jin, J., & Yang, C. C.-K. (2026) · Metabolites · doi:10.3390/metabo16070489 · Cited by 8
MASLD and the cardiovascular-kidney-liver-metabolic syndrome
Angelidi, A. M., Boutari, C., Kokkorakis, M., Stefanakis, K., Mikhailidis, D. P., Jacob, G., & Mantzoros, C. S. (2026) · Endocrine Reviews · doi:10.1210/endrev/bnag023 · Cited by 7
PARVB and HSD17B13 variants are associated with nonalcoholic fatty liver disease in children
Lee, K. J., Moon, J. S., Lim, J. G., Huh, H., Ahn, J. E., Kim, L., Kim, N. Y., & Ko, J. S. (2024) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.16521 · Cited by 4
“27 Moreover, another variant of HSD17B13 rs62305723 is associated with decreased ballooning and in fl ammation in patients with NAFLD.”
BackgroundInfluentialKamińska, D. (2024) · Genes · doi:10.3390/genes15091181 · Cited by 4
“This SNP inserts TA nucleotides, leading to premature termination of the HSD17B13 hepatic lipid-droplet protein, resulting in a truncated, non-functional protein [72].”
BackgroundRen, T., Chen, Q., & Zhu, C. (2025) · Clinical Nutrition ESPEN · doi:10.1016/j.clnesp.2025.04.026 · Cited by 5
Li, R., Su, K., Wu, T., Xu, L., Song, W., Sun, D., Zeng, T., Chen, J., Xin, H., Li, Y., et al. (2025) · BMC Genomics · doi:10.1186/s12864-025-11668-w · Cited by 4
“Additionally, GWASs have uncovered genetic variants implicated in NAFLD progression, such as rs72613567 (hydroxys-teroid 17-beta dehydrogenase 13, HSD17B13 ) [24] and rs4374383 (MER proto-oncogene, tyrosine kinase, MERTK ) [25].”
HCC in MASLD and ALD: Biochemical Pathways, Epidemiology, Diagnosis, and Treatment
Patel, S. A., Kasem, F., Flaherty, D. T., & Barve, A. J. (2025) · BioChem · doi:10.3390/biochem5030019 · Cited by 6
Metadata
- Authors
- Abul-Husn, N. S., Cheng, X., Li, A. H., Xin, Y., Schurmann, C., Stevis, P., Liu, Y., Kozlitina, J., Stender, S., Wood, G. C., Stepanchick, A. N., Still, M. D., McCarthy, S., O’Dushlaine, C., Packer, J. S., Balasubramanian, S., Gosalia, N., Esopi, D., Kim, S. Y., Mukherjee, S., Lopez, A. E., Fuller, E. D., Penn, J., Chu, X., Luo, J. Z., Mirshahi, U. L., Carey, D. J., Still, C. D., Feldman, M. D., Small, A., Damrauer, S. M., Rader, D. J., Zambrowicz, B., Olson, W., Murphy, A. J., Borecki, I. B., Shuldiner, A. R., Reid, J. G., Overton, J. D., Yancopoulos, G. D., Hobbs, H. H., Cohen, J. C., Gottesman, O., Teslovich, T. M., Baras, A., Mirshahi, T., Gromada, J., & Dewey, F. E.
- Affiliations
- From the Regeneron Genetics Center (N.S.A.-H., A.H.L., C.S., S. McCarthy, C.O., J.S.P., S.B., N.G., S. Mukherjee, A.E.L., E.D.F., J.P., I.B.B., A.R.S., J.G.R., J.D.O., O.G., T.M.T., A.B., F.E.D.) and Regeneron Pharmaceuticals (X. Cheng, Y.X., P.S., Y.L., D.E., S.Y.K., B.Z., W.O., A.J.M., G.D.Y., J.G.), Tarrytown, NY; the University of Texas Southwestern Medical Center at Dallas, Dallas (J.K., S.S., H.H.H., J.C.C.); and Geisinger Health System, Danville (G.C.W., A.N.S., M.D.S., X. Chu, J.Z.L., U.L.M....
- Regeneron (United States) (US)
- The University of Texas Southwestern Medical Center (US)
- Geisinger Health System (US)
- University of Pennsylvania (US)
- ORCID
- Cheng, Xiping
- Li, Alexander H.
- Xin, Yurong
- Schurmann, Claudia
- Liu, Yashu
- Kozlitina, Julia
- Stender, Stefan
- Wood, G. Craig
- Still, Matthew D.
- O’Dushlaine, Colm
- Packer, Jonathan S.
- Balasubramanian, Suganthi
- Gosalia, Nehal
- Esopi, David
- Kim, Sun Y.
- Mukherjee, Semanti
- Lopez, Alexander E.
- Chu, Xin
- Luo, Jonathan Z.
- Mirshahi, Uyenlinh L.
- Carey, David J.
- Still, Christopher D.
- Feldman, Michael D.
- Small, Aeron
- Damrauer, Scott M.
- Rader, Daniel J.
- Zambrowicz, Brian
- Olson, William
- Murphy, Andrew J.
- Borecki, Ingrid B.
- Shuldiner, Alan R.
- Reid, Jeffrey G.
- Overton, John D.
- Hobbs, Helen H.
- Cohen, Jonathan C.
- Baras, Aris
- Mirshahi, Tooraj
- Gromada, Jesper
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2018-03-22
- Volume
- 378
- Issue
- 12
- Pages
- 1096-1106
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC6668033
- OpenAlex
- W2793543636
- Cited by
- 827
- References
- 32
- Citations by year
- 2026: 101 · 2025: 104 · 2024: 82 · 2023: 104 · 2022: 100 · 2021: 109 · 2020: 127 · 2019: 67 · 2018: 32
- FWCI
- 48.13
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- Regeneron Pharmaceuticals
- Perelman School of Medicine, University of Pennsylvania
- Smilow Foundation
- National Institutes of Health (P30DK072488, UL1TR001105)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic Associations and Epidemiology
- Health Sciences › Medicine › Pathology and Forensic Medicine › Alcohol Consumption and Health Effects
- Keywords
- HSD17B13, chronic liver disease, loss-of-function mutations, alcoholic liver disease, non-alcoholic liver disease, alcoholic cirrhosis, non-alcoholic cirrhosis, nonalcoholic steatohepatitis, steatosis, alanine aminotransferase, aspartate aminotransferase, PNPLA3, liver histopathology
- MeSH terms
- Exome Sequencing, Loss of Function Mutation, Alanine Transaminase, Aspartate Aminotransferases, Chronic Disease, Fatty Liver, Female, Genotype, Humans, Liver, Liver Diseases, Male, Genetic Variation, 17-Hydroxysteroid Dehydrogenases, Biomarkers, Linear Models, Sequence Analysis, RNA, Disease Progression, Genetic Predisposition to Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.